Bicara Therapeutics
BCAX
172 hedge funds and large institutions have $2.07B invested in Bicara Therapeutics in 2026 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 67 increasing their positions, 39 reducing their positions, and 11 closing their positions.
264% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 11
72% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 39
53% more capital invested
Capital invested by funds: $1.35B → $2.07B (+$722M)
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
19% more funds holding
Funds holding: 145 → 172 (+27)
19.49% less ownership
Funds ownership: 125.72% → 106.24% (-19%)
67% less call options, than puts
Call options by funds: $2.09M | Put options by funds: $6.26M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$22.4M |
| 2 |
JP Morgan Chase
New York
|
+$18.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$14M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.8M |
| 5 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$9.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$32.3M |
| 2 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$22.9M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$13.8M |
| 4 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$12.7M |
| 5 |
O
OrbiMed
New York
|
-$10.6M |
BCAX Hedge Fund Activity: Q2 2026 in Review
172 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Bicara Therapeutics (BCAX) for Q2 2026, worth a combined $2.07B — up 53% from $1.35B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new BCAX positions and 11 closed out — a net gain of 29 holders — while 67 added to existing stakes and 39 trimmed.
The largest buyer was BlackRock, adding an estimated $22.4M. The largest seller was Citadel Advisors, cutting an estimated $32.3M.
- 172 institutional investors held Bicara Therapeutics (BCAX) as of Q2 2026, up from 145 in Q1 2026.
- Funds reported $2.07B of Bicara Therapeutics stock for Q2 2026, up 53% quarter-over-quarter.
- 40 funds opened new Bicara Therapeutics positions in Q2 2026 and 11 closed out, a net change of +29 holders.
- The largest Bicara Therapeutics buyer in Q2 2026 was BlackRock, an estimated $22.4M added.
- The largest Bicara Therapeutics seller in Q2 2026 was Citadel Advisors, an estimated $32.3M sold.
Based on aggregated 13F filings for Q2 2026.